{"id":829709,"date":"2025-03-25T16:35:30","date_gmt":"2025-03-25T20:35:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/"},"modified":"2025-03-25T16:35:30","modified_gmt":"2025-03-25T20:35:30","slug":"abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/","title":{"rendered":"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025"},"content":{"rendered":"

\nAbpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102\/CT-P72
\n<\/h2>\n
\n

WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) — Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102\/CT-P72 at the American Association for Cancer Research\u24c7<\/sup> Annual Meeting 2025 (\u201cAACR 2025\u201d) in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago.<\/p>\n

\n Invited speaker presentation details<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n
\n Title:<\/strong>\n <\/td>\nABP-102\/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with normal HER2 expression levels<\/td>\n<\/tr>\n
\n Session:<\/strong>\n <\/td>\nNew Drugs on the Horizon: Part 1<\/td>\n<\/tr>\n
\n Session Date:<\/strong>\n <\/td>\nSunday, April 27, 2025<\/td>\n<\/tr>\n
\n Session Time:<\/strong>\n <\/td>\n1:00 pm to 2:30 pm CDT<\/td>\n<\/tr>\n
\n Presenter:<\/strong>\n <\/td>\nAdam J. Pelzek, Ph.D., Associate Director, Abpro<\/td>\n<\/tr>\n
\n Abstract & Data:<\/strong>\n <\/td>\nEmbargoed until time of presentation<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About ABP-102\/CT-P72<\/strong>
\n
ABP-102\/CT-P72 an investigational HER2 x CD3 bispecific T-cell engager designed using Abpro\u2019s proprietary DiversImmune\u00ae platform to selectively target HER2-overexpressing tumor cells while reducing activity in HER2-low expressing normal tissues. Its tetravalent IgG1-[L]-scFv format enables bivalent HER2 binding with functionally monovalent CD3 engagement and is designed to optimize tumor selectivity and reduce cytokine-related toxicity. Abpro has an exclusive collaboration with Celltrion, a leading South Korean biotechnology company ranked among the world\u2019s top 25 by market capitalization, to advance ABP-102\/CT-P72 in development for the treatment of HER2+ breast, gastric, pancreatic, colorectal, and other cancers.<\/p>\n

\n About Abpro<\/strong>
\n
Abpro\u2019s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using Abpro’s proprietary DiversImmune\u00ae platform. Abpro is located in Woburn, Massachusetts. For more information, please visit www.abpro.co<\/a><\/u>.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
Abpro Contacts\r\nCompany: info@abpro.co\r\nInvestors: ir@abpro.co\r\nMedia: pr@abpro.co<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
Abpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102\/CT-P72 WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) — Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102\/CT-P72 at the American Association for Cancer Research\u24c7 Annual Meeting 2025 (\u201cAACR 2025\u201d) in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago. Invited speaker presentation details Title: ABP-102\/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with normal HER2 expression levels Session: New Drugs on … <\/p>\n
Continue reading “Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829709","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAbpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Abpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102\/CT-P72 WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) — Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102\/CT-P72 at the American Association for Cancer Research\u24c7 Annual Meeting 2025 (\u201cAACR 2025\u201d) in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago. Invited speaker presentation details Title: ABP-102\/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with normal HER2 expression levels Session: New Drugs on … Continue reading "Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T20:35:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODcxMyM2ODExODk4IzIwOTkyMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\\\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025\",\"datePublished\":\"2025-03-25T20:35:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/\"},\"wordCount\":346,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODcxMyM2ODExODk4IzIwOTkyMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/\",\"name\":\"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\\\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODcxMyM2ODExODk4IzIwOTkyMjc=\",\"datePublished\":\"2025-03-25T20:35:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODcxMyM2ODExODk4IzIwOTkyMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5ODcxMyM2ODExODk4IzIwOTkyMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\\\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/","og_locale":"en_US","og_type":"article","og_title":"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - Market Newsdesk","og_description":"Abpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102\/CT-P72 WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) — Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102\/CT-P72 at the American Association for Cancer Research\u24c7 Annual Meeting 2025 (\u201cAACR 2025\u201d) in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago. Invited speaker presentation details Title: ABP-102\/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with normal HER2 expression levels Session: New Drugs on … Continue reading \"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T20:35:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODcxMyM2ODExODk4IzIwOTkyMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025","datePublished":"2025-03-25T20:35:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/"},"wordCount":346,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODcxMyM2ODExODk4IzIwOTkyMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/","name":"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODcxMyM2ODExODk4IzIwOTkyMjc=","datePublished":"2025-03-25T20:35:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODcxMyM2ODExODk4IzIwOTkyMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5ODcxMyM2ODExODk4IzIwOTkyMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-oral-presentation-of-first-preclinical-data-for-abp-102-ct-p72-a-tetravalent-bispecific-her2-x-cd3-t-cell-engager-at-aacr-annual-meeting-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Abpro Announces Oral Presentation of First Preclinical Data for ABP-102\/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829709"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829709\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}